US 11,987,621 B2
Antibodies for IL-17C
Jan Dominik Haas, Munich (DE); Jürgen Klattig, Peißenberg (DE); and Nick Ernest René Vandeghinste, Mechelen (BE)
Assigned to MORPHOSYS AG, Planegg (DE); and GALAPAGOS NV, Mechelen (BE)
Filed by MORPHOSYS AG, Planegg (DE); and GALAPAGOS NV, Mechelen (BE)
Filed on Mar. 18, 2020, as Appl. No. 16/822,844.
Application 16/822,844 is a division of application No. 16/286,231, filed on Feb. 26, 2019, granted, now 10,633,439.
Application 16/286,231 is a continuation of application No. 16/058,143, filed on Aug. 8, 2018, granted, now 10,259,869, issued on Apr. 16, 2019.
Application 16/058,143 is a continuation of application No. PCT/EP2017/053592, filed on Feb. 17, 2017.
Claims priority of application No. 16156582 (EP), filed on Feb. 19, 2016; and application No. 16156651 (EP), filed on Feb. 22, 2016.
Prior Publication US 2020/0216529 A1, Jul. 9, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01); A61K 39/395 (2006.01)
CPC C07K 16/244 (2013.01) [C12N 15/62 (2013.01); C12N 15/63 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 17 Claims
 
1. A method for treating a subject suffering from an inflammatory disorder, comprising administering to said subject an effective amount of an antibody or antibody fragment comprising
a) a HCDR1 region comprising the amino acid sequence of SEQ ID NO: 7, a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 8, a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 9, a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 13, a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 14 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO: 15, or
b) a HCDR1 region comprising the amino acid sequence of SEQ ID NO: 20, a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 21, a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 22, a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 26, a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 27 and a LCDR3 region comprising the amino acid sequence of SEQ ID NO: 28.